Benzinga's Top #PreMarket Gainers

Loading...
Loading...
Orexigen Therapeutics, Inc.OREX
shares gained 10.62% to $8.02 in the pre-market trading session following Thursday's EC approval of Mysimba.
BioMarin Pharmaceutical Inc. BMRN
gained 9.61% to $126.65 in pre-market trading on rumor of Shire interest. Deutsche Bank lifted the price target on the stock from $90 to $140.
The Dow Chemical CompanyDOW
shares rose 4.78% to $49.10 in pre-market trading after the company announced its plans to spin off Chlor Alkali unit to merge that unit with Olin Corp
OLN
.
Esperion Therapeutics, Inc. ESPR
shares climbed 4.03% to $92.07 in pre-market trading. Citigroup assumed Esperion Therapeutics with a Buy rating and a $130.00 price target, according to Reuters.
Finish Line Inc. FINL
shares surged 3.38% to $24.75 in pre-market trading after the company reported better-than-expected results for the fiscal fourth quarter.
Posted In: NewsPre-Market OutlookMarketsMoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...